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Background: European medical device regulation is under scrutiny and will be re-regulated with stricter rules
concerning requirements for clinical evidence for high-risk medical devices. It is the aim of this study to analyse the
differences between Europe and USA in dealing with risks and benefits of new cardio-vascular devices.
Methods: Since no information is available on clinical data used by the Notified Body for CE-marking, data from
Austrian pre-reimbursement assessments close to European market approval were used as proxy and compared
with clinical data available at time of market approval by FDA in the USA.
Results: 10 cardio-vascular interventions with 27 newly CE approved medical devices were analysed. The time lag
between market authorisation in Europe and in the USA is 3 to 7 years. Only 7 CE-marked devices also hold a FDA
market approval, 7 further devices are in FDA approved ongoing efficacy trials. For 4 of the CE-marked devices
the FDA market application or the approval-trial was either suspended due to efficacy or safety concerns or the
approval was denied. Evidence available at time of CE-marking are most often case-series or small feasibility RCTs,
while large RCTs and only in rare cases prospective cohort studies are the basis of FDA approvals. Additionally, the
FDA often requires post-approval studies for high-risk devices.
Conclusions: Market authorisation based on mature clinical data deriving from larger RCTs and longer follow-ups
do not only change the perspective on the risk-benefit ratio, but also secures real patient benefit and safety and
assures payers of investing only in truly innovative devices.
Keywords: Approval, Market authorisation, Medical devices, Evidence based medicine/EbM, Health Technology
Assessment/HTA, Cardio-vascular disease, Surgery, SafetyBackground
Because of several market withdrawals due to unsafe or
ineffective devices, European medical device regulation
is under scrutiny and will be re-regulated with stricter
rules concerning requirements for clinical evidence for
class III (active) and class IIb (inactive) implantable
medical devices [1]. The criticism from health care pro-
viders [2,3] as well as from pre-coverage health tech-
nology assessors (HTA) and payers [4-6], but also from
patient groups [5] is nurtured by the fact that unsafe* Correspondence: Claudia.wild@hta.lbg.ac.at
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unless otherwise stated.devices reach the European markets with pre-mature cli-
nical data. Re-regulation details are still under debate: It
has been suggested to reduce the number of European
market authorisation agencies (“Notified Bodies/NB”)
from the current 75 to a few certified ones to approve
highly specialised devices or to even go for complete cen-
tralisation, as is the case with drugs. Another suggestion is
to transparently document the approval process, the evi-
dence requirements and the provided clinical data [7].
It is well known that new medical devices, including all
high-risk cardio-vascular devices, receive the European
market approval (CE/ Conformité Européenne mark)
several years prior to USA market authorisation [2]. Dued. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and what the decentralised NBs receive as application in-
formation, the actual clinical evidence can only be specu-
lated via clinical studies published after the CE mark was
issued.
Still, because of pressure from physician groups wish-
ing to offer patients early access to innovative medicine
and from manufacturers wishing early market expansion,
applications for coverage of those newly CE marked de-
vices are submitted to reimbursement institutions only
several months later [8]. In a recent analysis of seven de-
vices from all medical disciplines, it could be shown that
Austria is among the first countries where applications
for uptake and inclusion into the benefit catalogue are put
forward [8]. Since 2008, the Ludwig Boltzmann Institute
for HTA (LBI-HTA) has been commissioned by the
Austrian Ministry of Health (MoH) to assess new hospital
interventions, whereby new high-risk cardio-vascular im-
plantable devices have accounted for one-third of all pri-
mary assessments.
The aim of this study is to analyse what evidence was
available for cardio-vascular devices at the time of CE
marking using the evidence presented in the Austrian
assessments as a proxy, and to compare this data with
the data available at the time of FDA (Food and Drug
Administration) approval. Thereby, we intend to chal-
lenge the argument that earlier provision of new devices
is always of benefit to the patient.
Methods
Since no information is available on clinical data used by
the NB for CE marking and because the Austrian pre-
reimbursement assessments are rather close to CE mar-
king, we assumed that the clinical evidence – provided
by the manufacturer – used for CE mark could be con-
sidered a subset of the one used for the assessments pro-
duced for deciding on including the interventions in the
hospital benefit catalogue. For this study we assumed
the evidence is the same. Out of all pre-reimbursement
assessments we selected those that dealt with cardio-
vascular interventions. Since the intention of the analysis
was to concentrate on the level of evidence of new me-
dical devices, we excluded those assessments that dealt
with a) interventions where no new (defined by us as
max. 3–5 years prior to assessment) CE marked products
were available at the time of assessment, b) expansion of
established indications (new interventions) with already
existing products, and c) cerebro-vascular interventions.
From the included assessments (published between
2006 and 2014) we extracted information on a) inter-
vention, b) devices, c) indication and d) best available
evidence in terms of number and types of studies and
number of study participants. Furthermore, we searched
for publicly available online information on CE marking(spring 2014) and, in cases of missing information, con-
tacted the manufacturers directly, rather than consulting
the NANDO (New Approach Notified and Designated
Organisations) Database.
In the USA, new high-risk devices typically undergo a
premarket approval (PMA) process based on an efficacy
trial [9]. Devices can receive an IDE status (investi-
gational device exemption) that allows the device to be
used in clinical approval trials [10]. Moreover, by de-
fining so-called HDE conditions (humanitarian device
exemption), it is intended that patients with a disease
manifested in fewer than 4,000 individuals benefit from
a device [11]. To obtain information on the time of FDA
approval and on available evidence at the time of ap-
proval, we searched for PMA, IDE, and HDE documents
related to the selected interventions and devices (June to
July 2014). Again, data on clinical evidence for PMA de-
cisions and trial information were extracted.
Next, we assigned the levels of clinical evidence accor-
ding to the Oxford Centre for Evidence-based Medicine
hierarchy: 1: SR (systematic review) or MA (meta-analysis)
based on several high quality RCTs (randomized clinical
trials); 2: at least 1 RCT of high quality; 3: CTs (controlled
trials) without randomisation; 4: prospective case–control
and cohort studies; 5: case reports and retrospective case
series [12].
Finally, we compared the market authorisation status
and the level of evidence available around the time of
market authorisation between Europe and the USA.
Moreover, we analysed in more detail the differences
between Europe and the USA in dealing with clinical
evidence and with risk-benefit evaluations.Results
Between 2008 and 2014, 15 (out of 48) pre-reimbursement
assessments dealt with cardio-vascular interventions. From
those, assessments on 10 cardio-vascular interventions
were finally included into the analysis according to the
pre-defined criteria (Table 1).Market authorisation granted
For the 10 cardio-vascular interventions analysed, 27
newly approved CE marked medical devices were avail-
able (see details in Table 2). Of those, only 6 devices also
hold a PMA status, 1 holds the HDE status, while 7
medical devices are under IDE. For 4 of the devices, the
application in the USA was either suspended due to effi-
cacy or safety concerns before/during/after the IDE trials
(Cotovance™, Ventana™, Symplicity™), or market author-
isation was denied (Watchman®) due to safety concerns.
12 CE marked cardio-vascular devices are neither PMA-
approved, nor hold an IDE status (yet), meaning that
they are produced solely for the European market or the
Table 1 Cardio-vascular interventions and medical devices, years of approval in Europe and in the USA, year of reimbursement-application in Austria
(2008–2014)









1. Percutaneous pulmonary valve
implantation for right
ventricular outflow tract
dysfunction in patients with
congenital heart defects
Melody™/Medtronic Patients born with a
dysfunctional conduit of the
right ventricular outflow tract
(RVOT)
2006 2008 2010 4 years
Jan: HDE Melody™




Inoperable or high-risk patients
with severe aortic valve stenosis
2010 2008 2014 4 years
2011 Updates: 2009,
2010, 2011





modulation (CCM) for heart
failure
Optimizer™ III/Impulse Dynamics Patients with symptomatic heart
failure, NYHA Stadium ≥ II and
normal QRC complex in ECG




angioplasty (PTA) of periphery
arteries with drug-eluting
balloon (DEB)
In.Pact™ Amphirion + Admiral/
Medtronic
Patients with peripheral artery
diseases, including extracranial
carotid and vertebral artery
disease, upper extremity artery
disease, mesenteric artery
disease, renal artery disease as
well as lower extremity artery
disease
In.Pact™: 2009 2013 2014 5 years





2011LEGflow™: 2011/2012Advance 18 PTX®/Cook Medical
LEGflow™/Cardionovum









Please DCB/Braun Melsungen AG
Patients with coronary artery
diseases with in-stent-restenosis
(ISR), ostium stenosis, stenosis of
small coronary vessel disease
(SVD) and de-novo lesion of
coronary vessels
Dior® PCB: 2007 2009 No PMA -
SeQuent® Please DCB: 2009 Update: 2013
In.Pact™ Admiral: 2009In.Pact™ Admiral/Medtronic
Cotavance™/Bayer Schering Cotavance™: 2011
6. Percutaneous repair of mitral
regurgitation with the
MitraClip
MitraClip®/Abbott Patients with moderately severe
or severe mitral regurgitation
(grade 3+ or 4+); both operable
and inoperable patients
2008 2010 2013 5 years
Update: 2012 March: PMA
MitraClip®/Abbott
7. Renal Denervation Symplicity™ RDN/Medtronic Patients with therapy resistant
hypertonia after unsuccessful
treatment (no blood pressure
decrease) with at least 3
antihypertensive medicaments





















Table 1 Cardio-vascular interventions and medical devices, years of approval in Europe and in the USA, year of reimbursement-application in Austria
(2008–2014) (Continued)




Patients with abdominal aortic
aneurysm and/or iliacal aneurysm




2013 2012 7 years
Zenith® Fenestrated





angioplasty (PTA) with drug-
eluting stents in peripheral





peripheral artery disease (PAD)
on arteria femoralis superficialis/










XIENCE Prime BTK: 2011
S.M.A.R.T.®/Cordis
Infrapopliteal: Yukon®: 2011




10. Percutaneous left atrial
appendage closure for the
prevention of
thromboembolic events in




Patients with atrial fibrillation
(AF)/flutter/cardiac arrhythmia/
abnormal heart rhythm to
prevent thromboembolic events
such as ischaemic stroke
Watchman® LAA: 2005,
2012 (extended use)




























Table 2 Evidence available at time of pre-reimbursement assessment in Austria and at time of FDA approval, levels of evidence
Intervention Product Highest level of evidence at
time of pre-reimbursement
assessment (Austria)




1. Percutaneous pulmonary valve
implantation for right
ventricular outflow tract
dysfunction in patients with
congenital heart defects
Melody™ NB 2006 FDA 2010 4
2008 [14]: 4 retrospective +
prospective case series, 8–68 pts
5 HDE approval based on 1
prospective case series 99 pts,
requirement of 2 post-approval
studies with 5y FU [13]
2. Percutaneous aortic valve
replacement/ TAVI
CoreValve® 2007 FDA 2014 2
SAPIEN XT™ 2008 [16]: retrospective +
prospective 10 case series, 8–86
pts
5 CoreValve® PMA approval based
on 1 RCT, 656 pts [15] (CoreValve
U.S. Pivotal Trial), requirement for
post-approval study on extreme
risk patients.2009 [18]: see 2008 + 4 case
series, 12–646 pts 2010 [19]: see
2008 + 2009 + 6 cohort studies
(registries), 4 HTAs
4
4 SAPIEN XT™ PMA approval based
on 1 RCT, 560 pts [17] (PARTNER
II), requirement for post-approval




2011 [20]: see 2008 + 2009 +
2010 + 1 RCT, 358 pts (PARTNER I)
3. Cardiac contractility
modulation (CCM) for heart
failure
Optimizer™ III/IV NB 2007 - -
2008 [21]: 2 RCTs, 49/164 pts
(FIX-HF-4/ OPTIMIZER) +2 case
series 13/25 pts)
2 IDE Status: Optimizer™ III
Optimizer™ III/IV Trial FIX-HF-5
(Evaluate Safety and Efficacy of
the OPTIMIZER®) ongoing
2009 [22]: see 2008 + 1 RCT-
Protokoll, 428 pts (FIX-HF-5/
OPTIMIZER)
2
2010 [23]: see 2009 2
4. Percutaneous transluminal
angioplasty (PTA) of periphery
arteries with drug-eluting
balloon (DEB)
In.Pact™ Amphirion + Admiral NB 2009/11/12/13 FDA 2014 1 + 3
2013 [25]: 4 RCTs, 50–102 pts(2 ×
In.Pact™ DEBELLUM, PACIFIER, 2 ×
Cotovance™ THUNDER, FemPac)
+2 cohort studies (registries:
In.Pact™ Admiral, In.Pact™
Amphirion)
1-2 Lutonix DCB® PMA based on
LEVANT 2 RCT, 476 pts + LEVANT
2 registry, 657 pts. [24]
Lutonix DCB®
Cotavance™
Advance 18 PTX® IDE Status: In.Pact™ Admiral
based on SFA I and SFA II RCT,
331 pts
LEGflow™ No IDE Status: Cotavance™ (IDE
suspended), Advance 18 PTX





























SeQuent® DCB In.Pact™ Admiral 2009 [26]: 2 RCTs, 52/108 pts
(2x Cotavance™ PACCOCATH I, II)
1-2 IDE Status: In.Pact™ Admiral/
Medtronic based on SFA I and
SFA II RCT, 331 pts
Cotavance™ 2013 [27]: 5 RCTs for ISR, 50–271
pts (4 × SeQuent® PEPCAD II-IV +
1 × Cotavance™ PACCOCATH II
FU) +1 RCT for SVD, 60 pts (Dior®
PICCOLETO) +1 RCT for de-novo
lesions, 84 pts (SeQuent®)
1-2 No IDE Status :Dior® PCB (only
EU), SeQuent® DCB: (only EU),
Cotavance™ (IDE suspended)
6. Percutaneous repair of mitral
regurgitation with the
MitraClip
MitraClip®/Abbott NB 2008 4 FDA 2013
2010 [28]: prospective case series
(EVEREST I/II), 107 pts 2012 [30]:
2010 + 10 case series +1 RCT,
279 pts (EVEREST II)
2 MitraClip® PMA approval based
on EVEREST II RCT, 279 pts.,
EVEREST II high-risk registry
(EVEREST II HRR), 78 pts and
EVEREST II Cont. access registry
(REALISM HR), 853 pts [29],
requirement of 2 post-approval
studies (registries)
2 + 3
7. Renal denervation Symplicity™ RDN/Medtronic NB 2008 - -
2011 [31]: 1 prospective case
series (SYMPLICITY HTN-1), 50 pts;
1 RCT, 106 pts. (SYMPLICITY HTN-
2)
4, 2 IDE Status: IDE approval study
SYMPLICITY HTN-3, 535 pts.
failed; 2014 approval process




2012 [33]: 2011+ 1 case series,
153 pts. (FU SYMPLICITY HTN-1)




NB 2005/13 FDA 2012 4
2013 [34]: 2 HTAs +4 SR based
on 1 (non-randomised)
controlled study, 187 pts +7-20
case series, 196–368 pts
3 Zenith® Fenestrated AAA
Endovascular Graft PMA approval
based on 1 (historic case-)
controlled study, 42 pts [35],
requirement of a long-term
follow-up study.
Ventana™ Fenestrated System





















Table 2 Evidence available at time of pre-reimbursement assessment in Austria and at time of FDA approval, levels of evidence (Continued)
9. Percutaneous transluminal
angioplasty (PTA) with drug-
eluting stents in peripheral
arterial disease, upper limb
and thorax
Femoropopliteal: NB 2009/ 12/13 1 + 21 + 2 FDA 2012 Zilver® PTX® PMA
approval based on Zilver PTX





S.M.A.R.T.® 3 RCTs, 36–479 pts (1 × Zilver®
PTX study, 2 × S.M.A.R.T.®
SCIROCCO I + II) +1 non-
randomised CTs, 93 pts (Zilver®)
+1 case series, 787 pts.
IDE Status: S.M.A.R.T.® Vascular
Stent System
No IDE Status: Innova™ Peripheral
Vascular DES System (MAJESTIC
in Australia, New Zealand, EU);
XIENCE® Prime BTK;
Infrapopliteal:
XIENCE® Prime BTK Infrapopliteal Yukon®; PROMUS
Element™PlusDES BTK; CYPHER®
Select (discontinued to be
marketed)
Yukon® 4 RCTs, 50–200 pts (1 × XIENCE®
DESTINY, 1 × Yukon® YUKON-BTK,
2× CYPHER® ACHILLES) +3 non-
randomised CTs, 58–103 pts +3




10. Percutaneous left atrial
appendage closure for the
prevention of
thromboembolic events in
patients with atrial fibrillation
Watchman® LAA Closure
Technology
NB 2005/08/12/13 4 + 5 - -
2011 [38]: 4 case series, 64–180
pts; 1 cohort study/ registry, 73
pts; 1 RCT, 542 pts (Watchman®
PROTECT AF)
2009: Watchman® LAA Closure
Technology PMA approval based
on RCT, 707 pts (PROTECT AF)
declined [39]
AMPLATZER™ Cardiac Plug 3 + 2
Coherex WaveCrest™ LAA
Occlusion System
2014 [40]: 2011 + 3 FU studies of
PROTECT AF +
IDE Status: Watchman® LAA
Closure, re-application with RCT
PREVAIL, 407 pts; AMPLATZER™
Cardiac Plug (RESPECT), 980 pts3 case series, 52–86 pts +1
cohort study/ registry, n/a; 2
prospective CTs, 80/150 pts
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(CYPHER® Select), marketing was discontinued in Europe.
Time lag in market authorisation
For those 7 (6: PMA; 1: HDE) cardio-devices holding
European and US licences, the time lag between market
authorisation in Europe and in the USA amounted to 3
to 7 years.
Levels of evidence
The applications for coverage of new interventions and
devices in cardio-vascular pathologies were submitted
between 1 to 3 years after CE marking. In most of the
10 analysed interventions, the evidence available at the
time of pre-reimbursement assessment was either level
4–5 (retrospective, sometimes prospective case series
without control groups) or 2 (small RCTs/feasibility
studies for individual devices/1st generation). Non-
randomised controlled studies (level 3) or prospectively
planned registries (level 4) were seldom available. On
the contrary, IDE-accepted RCTs (level 2) or – in some
rare medical conditions – prospective case series or
cohort studies (level 3 and 4) were the basis for FDA
approval decisions in most cases (Table 2).
A detailed analysis of the efficacy and safety assessments
of individual devices seems to be more informative than
the levels of evidence per se. Several differences in dealing
with the evidence on benefit-risk ratios could be identified
and the following patterns have appeared:
1. Requirement of extensive follow-up for high-risk
devices: Melody™ was CE marked in 2006 and has
held an HDE approval since 2010. An HDE
application is not required to contain the final
results of scientifically valid clinical investigations,
but must contain sufficient information to determine
that the device does not pose an unreasonable or
significant risk and that the probable benefit to
health outweighs the risks [13]. Therefore, two
additional post-approval studies (150 patients,
follow-up of 5 years and 100 new patients with
primary analysis performed at 6 months) are required
by the FDA for Melody™ [41]; these studies are
ongoing. No such requirements exist in Europe, since
registries are voluntary. Edwards SAPIEN XT™ and
CoreValve® received a CE mark in 2010 and 2011, and
a PMA in 2014. The latter is based on RCTs with 560
(SAPIEN XT™) and 656 patients (CoreValve®)
respectively. This type of clinical data was not available
at the time of European market authorisation.
Follow-up data from post-approval studies on
inoperable and extreme risk patients is required by the
FDA for both devices. No such requirements were
defined at the time of EU market authorisation.2. Early approval in Europe and later demonstration of
inefficacy in RCT: Symplicity™ received CE marking
in 2008 based on a safety study (SYMPLICITY
HTN-1). In 2014, the FDA approval study
(SYMPLICITY HTN-3) failed to meet its primary
efficacy endpoint [42]. As a consequence, the
manufacturer is considering a suspension of
enrolment in the already ongoing SYMPLICITY
HTN-4 (IDE) trial.
3. Early approvals in Europe and safety concerns in the
USA: Three different devices were approved for
percutaneous left atrial appendage closure for the
prevention of thromboembolic events in patients
with atrial fibrillation in Europe between 2005 and
2013; none of them holds a PMA status.
WATCHMAN® LAA Closure Technology was
denied PMA in 2009 due to safety concerns. The
FDA Circulatory System Devices Panel concluded
(7 in favour, 5 opposed) that although short-term
efficacy had been demonstrated by the data available
from the PROTECT AF trial, longer term efficacy
had not been adequately demonstrated due to the
lack of available long-term data [39]. In late 2013,
the PREVAIL data was presented; a PMA decision is
pending [43].
4. Devices of unknown value: Optimizer™ received the
CE mark in 2007 based on a feasibility trial
(showing no improvement in primary endpoints
[21-23] and proceeded on to the IDE-approved
FIX-HF-5 trial that has been running since 2011.
Results are to be expected in 2015.
For PTA (percutaneous transluminal angioplasty)
of peripheral arteries with drug- eluting balloon
(DEB), 6 devices received the CE mark between
2009 and 2013. Only one of these (Lutonix DCB™)
also received PMA in 2014; another (In.Pact™
Admiral IDE) is expected to be approved by the
FDA in 2015 or later. One of the DEBs, Cotavance™,
is CE marked for the treatment of peripheral
arterial disease (PAD), as well as stenotic lesions in
the iliac and infrainguinal arteries, but the IDE
application was suspended in 2012 due to problems
concerning drug adhesion to the balloon and the
according safety concerns [44].
5. Devices of critical risk-benefit-ratio: MitraClip®
received CE marking in 2008 on the basis of case
series (EVEREST I); PMA followed in 2013.
Although an RCT (EVEREST II), a prospectively
planned registry (EVEREST II HRR) and a
“Real World Expanded Multi-center Study”
(REALISM HR) were submitted, FDA approval was
cautious, with 5 votes to 3 on whether the benefits
outweigh the risks and 4 votes to 5 on whether
there is a reasonable assurance of efficacy.
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aneurysms received CE marking in 2005 and 2013.
Only one is also approved in the USA (2012); the
other (Ventana™) holds an IDE, but the trial was
suspended and enrolment was stopped because of a
higher than expected number of re-interventions [45].Discussion
Recent publications showed that cardiovascular devices
receiving PMA (between 2000 and 2007) are often (63%)
based on non-randomised studies that lack adequate
strength and may be prone to bias [46], that effec-
tiveness endpoints are more often reported than safety
endpoints, and that patient comorbidities are only in-
completely reported [47]. Recalls are not uncommon,
especially for those devices that have been cleared via
the “substantial equivalence” process [48]. The US
watchdog institution Public Citizen called medical de-
vices in the USA “substantially unsafe” [49]. In contrast,
the European debate is being led – with the exemption
of the detailed analysis in [2] – on a much more general
level. There is only a general demand for stricter regula-
tion, since no data are available for analysis and there
is a lack of transparency concerning which NB gave
market authorisation on the basis of what type of clinical
evidence.
Because of the earlier market authorisation and the
lack of requirements other than the performance eva-
luation of medical devices in Europe (the lack of a de-
finition of “performance” is resulting in totally different
interpretations), the clinical evidence available at the
time of pre-reimbursement assessments is naturally
lower than some years later for market authorisation in
the USA [5,50,51]. Several unsafe and ineffective devices
are approved in the EU, but not in the USA [52]. The
perspective of manufacturers (and of some clinical ex-
perts) that early market access provides highly innova-
tive medicine to suffering patients [53] is held against
the perspective that little is known on the effectiveness
and on the risk-benefit ratio at the time of European
market authorisation. Patients are put at risk and health
care systems are put under pressure to invest in in-
terventions of unknown value [6]. Since some cardio-
vascular devices are seemingly intended for the non-US
market only, the uncertainty on their benefits and poten-
tial harms may never be resolved.
Based on our experiences from 7 years of pre-
reimbursement assessments [54], our study contributes
to the existing knowledge that not only earlier approvals
are based on limited data, but that more mature data
deriving from larger randomised trials and longer follow-
ups might also change the perspective on the risk-benefit
ratio entirely. The two most obvious examples of devices
that have been considered for market approval on bothcontinents and where different conclusions were drawn
are Symplicity™ and Watchman®. Others are less visible, but
still there: For Optimizer™ (CE marked in 2007), no convin-
cing evidence on efficacy has been demonstrated so far. In
the case of Cotavance™ (CE marked in 2011), steps towards
FDA approval were suspended due to problems concerning
drug adhesion to the balloon. For Ventana™ (CE marked
2013), enrolment into a trial was stopped because of a
higher than expected number of re-interventions. There
may even be more examples we are not aware of. Further
general deficiencies are well described by Fraser et al. [2].
This study has shortcomings: The biggest limitation is
the fact that no data on the clinical evidence for the CE
marking are available; we therefore had to rely on the in-
formation on available clinical studies derived from the
Austrian pre-reimbursement assessments. Nevertheless,
we think it is plausible that less rather than more clinical
data were available at an earlier stage, though probably not
all published. Additionally, only the devices for specific in-
dications mentioned in the pre-reimbursement applications
were assessed, meaning that other cardio-devices posing
problems after CE marking such as ProRhytm® and HD
Mesh Ablator® for the treatment of Atrial Fibrillation (AF)
were not included in this analysis.Conclusions
Our conclusions are that good clinical evidence at the
time of market authorisation not only secures real patient
benefit and safety, but also assures payers of investing only
in truly innovative devices. In addition, good clinical evi-
dence might ease market access for manufacturers and
make coverage in (hospital) benefit catalogues more pre-
dictable. There is a strong need for stricter device regula-
tion in Europe and compulsory, long-term follow-up in
order not to expose European patients to (often) prema-
ture experimental devices.
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